The National Health Surveillance Agency (Anvisa) warned last week about counterfeit batches of two medicines on sale in Brazil: Tysabri, indicated for the treatment of multiple sclerosis, and the Ozempic, indicated for the treatment of type 2 diabetes. The announcement related to Tysabri occurred after Biogen Brasil Produtos Farmacêuticos Ltda. inform Anvisa about the falsification of batch FF00336, valid until January 2026.
See too: New medicine with a GREATER effect than Ozempic is approved by Anvisa; know more
see more
It sounds like magic, but it's not: THESE two natural oils will make your...
Are you eating too much sugar? Here are 4 signs for you…
According to information from the laboratory, the batch was produced only for institutional and non-commercial purposes, with characteristics differing from the original medicine. Therefore, Anvisa ordered the seizure and prohibition of distribution, commercialization and use of the counterfeit product.
The same measure was adopted for Ozempic's batch LP6F832, valid for November 2025. According to Novo Nordisk, the company reported the batch as fake, as it does not consider this batch of pens valid. Therefore, Novo Nordisk announced on its website that consumers should be wary of very low prices and non-traditional sales outlets.
Anvisa recommends that health professionals and the population purchase medicines only in regulated establishments, always in complete packaging and upon issuance of a invoice. In the case of suspected counterfeit medicines, consumers should not use the product and need to contact the manufacturers to verify authenticity.
Furthermore, if counterfeiting is detected by a healthcare professional, Anvisa must be notified immediately. The report must preferably be made through the Notivisa system. In the case of patients, the complaint can be made to the ombudsman's office, through the FalaBR platform.
It is also possible to check the list of irregular products already identified in Brazil, which can be done through the query system on the Anvisa website. For more information, Anvisa has a public service telephone number at 0800-642-9782.
The person responsible for Tysabri in Brazil informed that there are errors in the product counterfeit, in lot FF00336. The company announced that there are spelling errors in the address of the company responsible for importing and distributing the product in Brazil, as well as a difference in the color of the orange and blue stripe on the packaging.
There is also a difference in the formatting of the letters and the absence of Braille inscription on the packaging. Therefore, it is possible to notice that the product is a counterfeit, and not the original medicine.